In a recent update from Contract Development and Manufacturing Organization (CDMO), there are early signs of growth in biotech funding and an increase in customer interest, particularly in differentiated offerings. While the upturn is still in its early stages and requires a few more consistent quarters to establish, there has been continued momentum in order intake, especially in patent-protected commercial manufacturing. Additionally, there has been an improvement in demand for generic active ingredients compared to the previous year, contributing to improved profitability through healthy sales growth, better business mix, and cost optimization initiatives.
Notably, the quality record of the company remains strong, with successful completion of USFDA inspections at their facilities. As for future investments, the focus will be on aligning with customers’ preference for integrated services, particularly in areas such as ADC, peptides, and proprietary drug development and manufacturing. The company is also adopting a customer-focused approach to promote cross-selling opportunities at global locations.
On the other hand, Complex Hospital Generic (CHG) has seen robust demand for sevoflurane and isoflurane in the US and emerging markets, with capacity expansion for inhalation anesthesia underway to meet growing demand. In the intrathecal segment, there has been growth through new customer acquisitions, with continued market share leadership for intrathecal baclofen in the USA. Efforts are being made to strengthen the supply chain for injectable painkillers, along with investments in portfolio expansion and specialty products.
The India Consumer Healthcare (ICH) sector has introduced 7 new products and 10 new SKUs in the first quarter of fiscal year 2025. Investments in media and commerce spend have been made to drive growth of Power Brands, with revenue from Power Brands increasing by 19% year-over-year and contributing significantly to overall revenue. The addition of CIR (geriatric care brand) to the list of Power Brands further strengthens the brand portfolio, alongside other well-known brands such as Little’s, Lacto Calamine, Polycrol, Tetmosol, and i-range. E-commerce has seen a significant growth of 37% compared to the previous year, leading the company to focus on expanding reach to general trade and alternative sales channels such as e-commerce and modern trade.
Overall, the CDMO, CHG, and ICH sectors are showing positive signs of growth and innovation, with strategic investments and initiatives in place to drive continued success.
For more information, please visit https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=publish
Source link
